Skip to main content

Table 1 Association of screening and treatment with breast cancer mortality in US women from 2000 to 2012

From: Do we still need breast cancer screening in the era of targeted therapies and precision medicine?

  Mortality reduction compared to 1975 (%) Contribution to the difference in mortality reduction in 2012 versus 2000 (%)
In 2000a In 2012b Difference Screening advances Chemotherapy advances Hormone therapy advances Trastuzumab
Overall 37 49 12 17 38 29 15
ER+/HER2− 39 51 12 19 39 42 0
ER+/HER2+ 39 58 19 12 22 25 41
ER−/HER2+ 29 45 16 11 32 0 57
ER−/HER2− 29 37 8 22 78 0 0
  1. aRelative to the estimated baseline rate of 64 deaths (model range, 56–73) per 100,000 women in 2000; bRelative to the estimated baseline rate of 63 deaths (model range, 54–73) per 100,000 women in 2012. ER oestrogen receptor, HER2 human epidermal growth factor receptor 2. Source: Plevritis et al. [6]